Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine
| Autor: | Tanja Bauer, Matthias Günther, Wolfgang Jilg, Jan Arne Holtz, Ruth Neuhaus, Ulrich Bienzle |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Graft Rejection Male Hepatitis B vaccine medicine.medical_treatment Immunization Secondary Liver transplantation medicine.disease_cause Risk Assessment Severity of Illness Index Cohort Studies Hepatitis B Chronic Adjuvants Immunologic Liver Function Tests Transplantation Immunology medicine Secondary Prevention Humans Hepatitis B Vaccines Prospective Studies Hepatitis B Antibodies Aged Hepatitis B virus Transplantation Hepatology business.industry Graft Survival Hepatitis B Middle Aged medicine.disease Liver Transplantation Vaccination Treatment Outcome Immunization Immunology Surgery Female Transplantation Tolerance Immunocompetence business Adjuvant Follow-Up Studies |
| Zdroj: | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 12(2) |
| ISSN: | 1527-6465 |
| Popis: | Patients after orthotopic liver transplantation (OLT) due to hepatitis B virus (HBV)-related disease are at risk of endogenous hepatitis B reinfection and may receive life long prophylaxis with hepatitis B hyperimmunoglobulin (HBIG). In a previous study 16 of 20 OLT patients were immunized successfully with an adjuvant hepatitis B vaccine. To maintain protective antibody levels under immunosuppressive therapy, 11 of these patients were revaccinated with a double dosed conventional hepatitis B vaccine. Median interval between last vaccination and booster was 24 months (range 22-31 months). Antibody titres against hepatitis B surface antigen (anti-HBs) were monitored at the day of booster vaccination (day 0), at day 7 and day 28. At day 0, all vaccinees but one had anti-HBs titres greater than 500 IU/L (median 1,925 IU/L, range 196-7,612 IU/L). Maximum antibody titres after previous vaccination declined by a median of 82% (range 47-96%). After booster vaccination the anti-HBs titre increased significantly by a median factor of 2.42 (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text